Zhejiang Medicine Co Ltd
SSE:600216
Zhejiang Medicine Co Ltd
Total Equity
Zhejiang Medicine Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Zhejiang Medicine Co Ltd
SSE:600216
|
Total Equity
¥11.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Equity
¥31.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Equity
¥59.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Equity
¥39.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Total Equity
¥32.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Equity
¥3.9B
|
CAGR 3-Years
127%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Zhejiang Medicine Co Ltd
Glance View
Zhejiang Medicine Co., Ltd., a stalwart in the pharmaceutical industry, traces its roots back to a time when China's economic landscape was rapidly transforming. Founded amidst the burgeoning wave of Chinese industrial expansion, the company made a calculated entry into the biopharmaceutical sector, a move that positioned it as an indispensable player in the realm of vitamins and antibiotics. Headquartered in the populous province of Zhejiang, the firm quickly honed its expertise in the manufacturing and export of fat-soluble vitamins, notably vitamin E, which became one of its hallmark products. Their robust production facilities and rigorous adherence to quality standards have not only fueled domestic demand but also secured a strong foothold in international markets, particularly Europe and the Americas. Zhejiang Medicine has crafted a diversified portfolio that spans active pharmaceutical ingredients (APIs) and advanced intermediates, offering a spectrum of products utilized by various health and pharmaceutical companies worldwide. A key revenue driver for the company lies in its vertical integration strategy, which enables it to maintain meticulous oversight over the entire production process, from raw materials to finished goods. The company’s commitment to R&D is evident in its investments in technology and innovation, allowing it to improve production efficiency and develop new compounds that cater to the evolving demands of the health sector. This approach not only insulates the company from market volatility but also fortifies its competitive position in a dynamic industry.
See Also
What is Zhejiang Medicine Co Ltd's Total Equity?
Total Equity
11.1B
CNY
Based on the financial report for Sep 30, 2025, Zhejiang Medicine Co Ltd's Total Equity amounts to 11.1B CNY.
What is Zhejiang Medicine Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
5%
Over the last year, the Total Equity growth was 7%. The average annual Total Equity growth rates for Zhejiang Medicine Co Ltd have been 6% over the past three years , 8% over the past five years , and 5% over the past ten years .